Abstract: Provided is a separation and recovery apparatus for continuously separating and recovering, from a resin mixture containing a resin containing a hydrolyzable polymer and a resin containing a nonhydrolyzable polymer, a hydrolytic component a of the hydrolyzable polymer A and the nonhydrolyzable polymer B, the apparatus including: a crushing unit that crushes the resin mixture a melting/discharging unit that melts a crushed product obtained by the crushing unit to form a fluid and discharges the fluid at a high pressure; and a hydrothermal reaction treatment unit that continuously subjects the fluid discharged from the melting/discharging unit to a hydrothermal reaction treatment, wherein, in the melting/discharging unit, the hydrolyzable polymer A is hydrolyzed, and the hydrolytic component a thereof is dissolved and transferred into water permeating a sintered alloy diaphragm, thereby separating the nonhydrolyzable polymer B.

Abstract: The present invention provides a method for producing an exosome, comprising a step of applying a cell to a cell culture module to culture the cell and a step of producing an exosome by the cell, wherein the cell culture module is provided with a polymer porous film and a casing having at least two culture medium in-flow/out-flow ports and having the polymer porous film placed therein.

Abstract: Disclosed herein are a crystal comprising a compound, which has ?-opioid receptor antagonistic action, few side effects, and high safety, and having high purity and excellent physical properties (stability, solubility, etc.), and a method for producing the crystal. The crystal is a crystal of a salt comprising: a compound represented by a formula (I) [wherein R2 is a hydrogen atom or a halogen atom, and R1 is a group selected from the group consisting of and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, and oxalic acid, or a hydrate thereof.

Abstract: Disclosed herein are a crystal comprising a compound, which has ?-opioid receptor antagonistic action, few side effects, and high safety, and having high purity and excellent physical properties (stability, solubility, etc.), and a method for producing the crystal. The crystal is a crystal of a salt comprising: a compound represented by a formula (I) [wherein R2 is a hydrogen atom or a halogen atom, and R1 is a group selected from the group consisting of and an acid selected from the group consisting of hydrochloric acid, hydrobromic acid, and oxalic acid, or a hydrate thereof.

Abstract: A battery bracket for attaching, to an electrically assisted moving body capable of supplementing a first driving force generated by human power with a second driving force generated by electrical power, and a battery for use in the electrically assisted moving body. This battery bracket includes an extension section extending in a prescribed direction, and a plurality of projection sections projecting from the extension section in a direction intersecting the prescribed direction. The plurality of projection sections are mutually spaced along the prescribed direction.

Abstract: A highly-responsive sensor for use in a power-assisted mobile object. The sensor for use in power-assisted mobile object includes: ring-shaped first and second magnets each having a north pole and a south pole along a circumferential direction, having a ring shape, and disposed so as to rotate with rotation of a drive shaft coaxially with each other; at least a pair of first hall elements and a pair of second hall elements that detect a magnetic field of the first magnet and the second magnet, respectively, and is disposed at a distance from each other in the circumferential direction; and a distortion unit that is configured to get distorted in the circumferential direction due to torque during rotation of the drive shaft and disposed such that the distortion changes relative positions of the first magnet and the second magnet in the circumferential direction.

Abstract: A compound represented by formula (1) or salt thereof and a production intermediate thereof are created. The compound exhibited an excellent antioxidation action in a microsome lipid peroxidation measuring system using a rat liver microsome. Therefore, the compound or salt thereof is useful as an antioxidant. The present invention also provides use of a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof for production of an antioxidant.

Abstract: A compound represented by formula (1) or salt thereof and a production intermediate thereof are created. The compound exhibited an excellent antioxidation action in a microsome lipid peroxidation measuring system using a rat liver microsome. Therefore, the compound or salt thereof is useful as an antioxidant. The present invention also provides use of a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof for production of an antioxidant.

Abstract: The present invention is to provide a process for producing a 2?-O-acetyl-4?-formyl-8,9-anhydroerythromycin A 6,9-hemiketal compound 4, and it provide a process for producing an erythromycin compound which comprises reacting a formylating agent with a 2?-O-acetylerythromycin A compound 2 to obtain 2-?-O-acetyl-4?-O-formylerythromycin A compound 3, then, acting an acid on Compound 3 to subject to hemiketalation, and then adding an aqueous basic solution in an aqueous solution to precipitate Compound 4 as free crystals.

Abstract: The present invention is to provide a process for producing a 2?-O-acetyl-4?-O-formyl-8,9-anhydroerythromycin A 6,9-hemiketal compound 4, and it provide a process for producing an erythromycin compound which comprises reacting a formylating agent with a 2?-O-acetylerythromycin A compound 2 to obtain 2?-O-acetyl-4?-O-formylerythromycin A compound 3, then, acting an acid on Compound 3 to subject to hemiketalation, and then adding an aqueous basic solution in an aqueous solution to precipitate Compound 4 as free crystals.

Abstract: The present invention is to provide a process for producing a 2′-O-acetyl-4″-O-formyl-8,9-anhydroerythromycin A 6,9-hemiketal compound 4, and it provide a process for producing an erythromycin compound which comprises reacting a formylating agent with a 2′-O-acetylerythromycin A compound 2 to obtain 2′-O-acetyl-4″-O-formylerythromycin A compound 3, then, acting an acid on Compound 3 to subject to hemiketalation, and then adding an aqueous basic solution in an aqueous solution to precipitate Compound 4 as free crystals.

Abstract: The present invention is to provide a process for producing an erythromycin compound by subjecting a 2′-O-acetyl-4″-O-formyl-11-oxo-8,9-anhydroerythromycin A 6,9-hemiketal compound 1 to alkylation, which comprises reacting Compound 1 with an alkylating agent in the presence of a base in a mixed solvent of 0.18 to 1.05 equivalent of water based on Compound 1 and an organic solvent to give a 2′-O-acetyl-4″-O-formyl-11-oxo-12-alkoxy-8,9-anhydroerythromycin A 6,9-hemiketal compound 3.

Abstract: The present invention discloses the compound represented by the formula (I) ##STR1## wherein R.sub.1 and R.sub.2 are hydrogen atoms, R.sub.3 represents a hydrogen atom, a hydroxyl group or an amino group, or R.sub.2 and R.sub.3 in combination represent .dbd.O or .dbd.NOR.sub.11, where R.sub.11 represents a hydrogen atom or a lower alkyl group, R.sub.4 and R.sub.5 in combination represent .dbd.O, Y represents --N(R.sub.6) (R.sub.7) or --N.sup.+ (R.sub.8) (R.sub.9) (R.sub.10)X.sup.- ; where R.sub.6 to R.sub.10 each represent a hydrogen atom, a lower alkyl group, etc., and X.sup.- represents an anion,a pharmaceutical composition containing the same and a process for producing the same.